Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ENZY's Cash to Debt is ranked higher than
70% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. ENZY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ENZY' s 10-Year Cash to Debt Range
Min: 0.46  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.92
ENZY's Equity to Asset is ranked higher than
87% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ENZY: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
ENZY' s 10-Year Equity to Asset Range
Min: 0.67  Med: 0.89 Max: 0.93
Current: 0.92
0.67
0.93
Interest Coverage No Debt
ENZY's Interest Coverage is ranked lower than
63% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ENZY' s 10-Year Interest Coverage Range
Min: 8.09  Med: 10000.00 Max: 9999.99
Current: No Debt
8.09
9999.99
F-Score: 4
Z-Score: 11.96
M-Score: 0.91
WACC vs ROIC
2.07%
5.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 11.95
ENZY's Operating margin (%) is ranked higher than
81% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. ENZY: 11.95 )
Ranked among companies with meaningful Operating margin (%) only.
ENZY' s 10-Year Operating margin (%) Range
Min: -1.51  Med: 14.76 Max: 18.1
Current: 11.95
-1.51
18.1
Net-margin (%) 14.11
ENZY's Net-margin (%) is ranked higher than
83% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. ENZY: 14.11 )
Ranked among companies with meaningful Net-margin (%) only.
ENZY' s 10-Year Net-margin (%) Range
Min: -3.75  Med: 14.64 Max: 17.54
Current: 14.11
-3.75
17.54
ROE (%) 4.93
ENZY's ROE (%) is ranked higher than
78% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ENZY: 4.93 )
Ranked among companies with meaningful ROE (%) only.
ENZY' s 10-Year ROE (%) Range
Min: 3.19  Med: 6.37 Max: 6.52
Current: 4.93
3.19
6.52
ROA (%) 4.53
ENZY's ROA (%) is ranked higher than
82% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. ENZY: 4.53 )
Ranked among companies with meaningful ROA (%) only.
ENZY' s 10-Year ROA (%) Range
Min: 5.71  Med: 9.90 Max: 12.16
Current: 4.53
5.71
12.16
ROC (Joel Greenblatt) (%) 9.33
ENZY's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. ENZY: 9.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENZY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 13.81  Med: 27.97 Max: 29.34
Current: 9.33
13.81
29.34
» ENZY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ENZY Guru Trades in Q3 2014

John Paulson 4,271,230 sh (unchged)
» More
Q4 2014

ENZY Guru Trades in Q4 2014

John Paulson 4,238,275 sh (-0.77%)
» More
Q1 2015

ENZY Guru Trades in Q1 2015

Jim Simons 54,200 sh (New)
John Paulson 4,238,275 sh (unchged)
» More
Q2 2015

ENZY Guru Trades in Q2 2015

Jim Simons 82,494 sh (+52.20%)
John Paulson 4,238,275 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 34.66
ENZY's P/E(ttm) is ranked higher than
55% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 36.10 vs. ENZY: 34.66 )
Ranked among companies with meaningful P/E(ttm) only.
ENZY' s 10-Year P/E(ttm) Range
Min: 16.71  Med: 46.08 Max: 146.67
Current: 34.66
16.71
146.67
Forward P/E 21.46
ENZY's Forward P/E is ranked higher than
55% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. ENZY: 21.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 32.10
ENZY's PE(NRI) is ranked higher than
55% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 35.00 vs. ENZY: 32.10 )
Ranked among companies with meaningful PE(NRI) only.
ENZY' s 10-Year PE(NRI) Range
Min: 8.88  Med: 20.33 Max: 55.87
Current: 32.1
8.88
55.87
P/B 1.72
ENZY's P/B is ranked higher than
86% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ENZY: 1.72 )
Ranked among companies with meaningful P/B only.
ENZY' s 10-Year P/B Range
Min: 0.99  Med: 1.63 Max: 11
Current: 1.72
0.99
11
P/S 4.96
ENZY's P/S is ranked higher than
73% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. ENZY: 4.96 )
Ranked among companies with meaningful P/S only.
ENZY' s 10-Year P/S Range
Min: 1.16  Med: 2.82 Max: 5.82
Current: 4.96
1.16
5.82
PFCF 484.50
ENZY's PFCF is ranked lower than
95% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 39.55 vs. ENZY: 484.50 )
Ranked among companies with meaningful PFCF only.
ENZY' s 10-Year PFCF Range
Min: 21.53  Med: 63.06 Max: 519
Current: 484.5
21.53
519
POCF 48.45
ENZY's POCF is ranked lower than
63% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. ENZY: 48.45 )
Ranked among companies with meaningful POCF only.
ENZY' s 10-Year POCF Range
Min: 9.88  Med: 37.60 Max: 1030
Current: 48.45
9.88
1030
EV-to-EBIT 33.15
ENZY's EV-to-EBIT is ranked lower than
51% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 27.86 vs. ENZY: 33.15 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZY' s 10-Year EV-to-EBIT Range
Min: 7.2  Med: 22.60 Max: 61.8
Current: 33.15
7.2
61.8
Current Ratio 8.04
ENZY's Current Ratio is ranked higher than
68% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ENZY: 8.04 )
Ranked among companies with meaningful Current Ratio only.
ENZY' s 10-Year Current Ratio Range
Min: 2.31  Med: 7.00 Max: 8.76
Current: 8.04
2.31
8.76
Quick Ratio 5.82
ENZY's Quick Ratio is ranked higher than
60% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. ENZY: 5.82 )
Ranked among companies with meaningful Quick Ratio only.
ENZY' s 10-Year Quick Ratio Range
Min: 1.5  Med: 5.46 Max: 7.31
Current: 5.82
1.5
7.31
Days Inventory 435.08
ENZY's Days Inventory is ranked lower than
94% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. ENZY: 435.08 )
Ranked among companies with meaningful Days Inventory only.
ENZY' s 10-Year Days Inventory Range
Min: 121.07  Med: 143.84 Max: 333.94
Current: 435.08
121.07
333.94
Days Sales Outstanding 121.38
ENZY's Days Sales Outstanding is ranked lower than
78% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. ENZY: 121.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZY' s 10-Year Days Sales Outstanding Range
Min: 108  Med: 117.86 Max: 128.19
Current: 121.38
108
128.19

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.94
ENZY's Price/Net Cash is ranked higher than
52% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. ENZY: 7.94 )
Ranked among companies with meaningful Price/Net Cash only.
ENZY' s 10-Year Price/Net Cash Range
Min: 5.38  Med: 7.72 Max: 10.39
Current: 7.94
5.38
10.39
Price/Net Current Asset Value 3.28
ENZY's Price/Net Current Asset Value is ranked higher than
80% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. ENZY: 3.28 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZY' s 10-Year Price/Net Current Asset Value Range
Min: 2.55  Med: 3.05 Max: 14.91
Current: 3.28
2.55
14.91
Price/Tangible Book 1.71
ENZY's Price/Tangible Book is ranked higher than
88% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. ENZY: 1.71 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZY' s 10-Year Price/Tangible Book Range
Min: 1.18  Med: 1.96 Max: 6.81
Current: 1.71
1.18
6.81
Price/Median PS Value 1.75
ENZY's Price/Median PS Value is ranked lower than
71% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. ENZY: 1.75 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZY' s 10-Year Price/Median PS Value Range
Min: 0.41  Med: 0.94 Max: 1.51
Current: 1.75
0.41
1.51
Price/Graham Number 1.64
ENZY's Price/Graham Number is ranked higher than
80% of the 169 Companies
in the Global Biotechnology industry.

( Industry Median: 3.18 vs. ENZY: 1.64 )
Ranked among companies with meaningful Price/Graham Number only.
ENZY' s 10-Year Price/Graham Number Range
Min: 0.87  Med: 1.54 Max: 3.35
Current: 1.64
0.87
3.35
Earnings Yield (Greenblatt) (%) 3.02
ENZY's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ENZY: 3.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.6  Med: 4.40 Max: 13.9
Current: 3.02
1.6
13.9

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 53 64
EPS($) 0.30 0.43
EPS without NRI($) 0.30 0.43

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:EZ4.Germany,
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
ENZYMOTEC 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General a Oct 31 2014 
Kessler Topaz Meltzer & Check, LLP Reminds Enzymotec Ltd. (ENZY) Shareholders of Class Action Lawsui Oct 15 2014 
Saxena White P.A. Files Securities Fraud Class Action Against Enzymotec Ltd. Oct 15 2014 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Enzymotec Ltd. Granted U.S. Patent for INFAT(R) to Promote Intestinal Development and Maturation Aug 20 2015
Enzymotec Ltd. Granted U.S. Patent for INFAT(R) to Promote Intestinal Development and Maturation Aug 19 2015
Will Enzymotec (ENZY) Continue to Surge Higher? Aug 17 2015
Enzymotec (ENZY) Catches Eye: Stock Soars 15.2% Aug 13 2015
Enzymotec upgraded by Wells Fargo Aug 13 2015
Enzymotec Ltd. Reports Second Quarter 2015 Results Aug 12 2015
Enzymotec beats 2Q profit forecasts Aug 12 2015
Enzymotec beats 2Q profit forecasts Aug 12 2015
Enzymotec Ltd. Reports Second Quarter 2015 Results Aug 12 2015
Q2 2015 Enzymotec Ltd Earnings Release - Before Market Open Aug 12 2015
Enzymotec Ltd. Announces the Appointment of Tamar Howson to Its Board of Directors Jul 30 2015
Enzymotec to Report Second Quarter 2015 Financial Results Jul 29 2015
Enzymotec to Report Second Quarter 2015 Financial Results Jul 29 2015
Enzymotec Ltd. Announces Investigator Initiated Clinical Trial of Vayarin(R) in Managing ADHD in... Jul 07 2015
Enzymotec Ltd. Announces Investigator Initiated Clinical Trial of Vayarin(R) in Managing ADHD in... Jul 07 2015
2015-06-15 Enzymatica rang in the company at Nasdaq First North Jun 15 2015
Enzymotec Ltd. Announces Annual General Meeting of Shareholders Jun 11 2015
2015-06-10 Enzymatica approved for listing on Nasdaq First North - trading to start June 15, 2015 Jun 10 2015
Will Enzymotec (ENZY) Continue to Surge Higher? - Tale of the Tape May 28 2015
Enzymotec Ltd. to Participate in the Jefferies 2015 Global Healthcare Conference May 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK